Brokers Issue Forecasts for RMTI Q1 Earnings

Rockwell Medical, Inc. (NASDAQ:RMTI) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Rockwell Medical in a research note issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.02) per share for the quarter. HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.06) EPS.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.04). The firm had revenue of $24.67 million for the quarter, compared to the consensus estimate of $23.65 million. Rockwell Medical had a positive return on equity of 8.55% and a negative net margin of 1.25%.

Separately, StockNews.com downgraded Rockwell Medical from a “buy” rating to a “hold” rating in a report on Friday, December 20th.

Rockwell Medical Trading Down 6.7 %

Shares of NASDAQ RMTI opened at $1.26 on Tuesday. The firm has a 50 day moving average price of $1.83 and a two-hundred day moving average price of $2.59. The stock has a market cap of $40.72 million, a P/E ratio of -25.20 and a beta of 1.55. Rockwell Medical has a 52-week low of $1.26 and a 52-week high of $5.15. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.00 and a current ratio of 2.41.

Institutional Trading of Rockwell Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of Rockwell Medical in the 4th quarter valued at $28,000. Two Sigma Securities LLC bought a new stake in Rockwell Medical during the fourth quarter valued at $33,000. Barclays PLC acquired a new stake in Rockwell Medical during the 3rd quarter worth about $90,000. XTX Topco Ltd raised its position in shares of Rockwell Medical by 45.7% in the 3rd quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after acquiring an additional 8,922 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Rockwell Medical by 134,397.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 47,074 shares of the company’s stock worth $187,000 after acquiring an additional 47,039 shares in the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.